Pricing Log in Create free account

Vaxcyte, Inc. (PCVX) vs TG Therapeutics, Inc. (TGTX)

Vaxcyte, Inc. and TG Therapeutics, Inc. are both Biotechnology companies. Vaxcyte, Inc. and TG Therapeutics, Inc. are of similar size ($9.8B and $9.4B). Vaxcyte, Inc. has negative trailing earnings, so its P/E is not meaningful; TG Therapeutics, Inc. trades at 19.7×. TG Therapeutics, Inc. has the higher net margin (55.2% vs 0.00%) and the higher return on invested capital (10.7% vs −57.3%). Across the 14 metrics below, TG Therapeutics, Inc. leads on 11 and Vaxcyte, Inc. on 3.

Valuation

Metric PCVX TGTX Biotechnology median
P/E n/m 19.74 10.71
P/S n/m 10.64 9.84
P/B 3.18 14.08 2.15
Price to free cash flow n/m 489.37 25.78
EV/EBITDA n/m 63.99 0.65
EV/Sales n/m 10.88 9.47
Earnings yield (12.55%) 5.07% (34.53%)
Free cash flow yield (10.18%) 0.20% (24.00%)

Profitability

Metric PCVX TGTX Biotechnology median
Gross margin 0.00% 82.37% 69.20%
Operating margin 0.00% 17.05% 0.00%
Net margin 0.00% 55.22% 0.00%
Free cash flow margin 0.00% 2.17% 0.00%
Return on equity (36.51%) 100.28% (53.10%)
Return on assets (33.03%) 37.70% (46.06%)
Return on invested capital (57.30%) 10.69% 0.00%

Growth

Metric PCVX TGTX Biotechnology median
Revenue growth (TTM) — 76.08% 5.26%
EPS growth (last fiscal year) (48.16%) 1,746.67% 29.88%
Revenue growth, 5-year CAGR — 426.73% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PCVX TGTX Biotechnology median
Debt to equity 0.00 1.23 0.00
Current ratio 5.72 4.27 4.98
Net debt to EBITDA 1.71 0.86 1.01

Dividend

Metric PCVX TGTX Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric PCVX TGTX Biotechnology median
Market cap 9.76b 9.36b 171.46m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack